Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients: 24-week immunological outcome

AIDS

Volumn 18, Issue 5, 2004, Pages 821-823

  Gianotti, Nicola ^a   Soria, Alessandro ^a   Galli, Laura ^a   Giudici, Barbara ^a   Fusetti, Giuliana ^a   Lazzarin, Adriano ^a   Boeri, Enzo ^b   Castagna, Antonella ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; LOPINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE DEPLETION; MULTIVARIATE ANALYSIS; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; RETREATMENT; SALVAGE THERAPY; T LYMPHOCYTE; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LINEAR MODELS; TREATMENT OUTCOME;

EID: 2042469458     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200403260-00018     Document Type: Article

References (5)

1. Hertogs K, Bloor S, Kemp SD, Van der Eynde C, Alcorn TM, Rauwels R, et al. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS 2000, 14: 1203-1210.
2. Harrigan PR, Larder BA. Extent of cross-resistance between agents used to treat human immunodeficiency virus type 1 infection in clinically derived isolates. Antimicrob Agents Chemother 2002, 46:909-912.
3. Phenix BN, Angel JB, Mandy F, Kravcik S, Parato K, Chambers KA, et al. Decreased HIV-associated T cell apoptosis by HIV protease inhibitors. AIDS Res Hum Retroviruses 2000, 16: 559-567.
4. Martinez-Picado J, Savara AV, Sutton L, D'Aquila RT. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J Virol 1999, 73:3744-3752.
5. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001, 344:472-480.